IFLR1000

ADC Therapeutics NYSE IPO

19/5/2020
IPO
Select tab

$ 267 million

Completed

19/5/2020

Overview:

  • Oncology-focused biotech company ADC Therapeutics successfully completed its initial public offering of 14 million shares on the New York Stock Exchange. 
  • The Swiss company's IPO, at $19 per share, made gross proceeds of $267 million. 
  • Morgan Stanley, BofA Securities and Cowen and Company acted as joint bookrunning managers.

Natasha Forrest - Researcher

Jurisdictions:

Switzerland
New York

Deal type:

IPO

Practice area:

Capital markets : Equity

Industry sector:

Pharmaceuticals and life sciences

Firms:
Davis Polk & Wardwell

Party: ADC Therapautics (Issuer)

Lawyer: Deanna Kirkpatrick

Homburger

Party: ADC Therapeutics (Issuer)

Lawyers: Benjamin Leisinger, Dieter Gericke

Lenz & Staehelin

Party: Morgan Stanley & Co (Underwriter)

Party: BofA Securities (Underwriter)

Party: Cowen and Company (Underwriter)

Lawyer: Jacques Iffland

Related deals